Chief Medical Officer at resTORbio.
Dr. Mannick is Co-Founder and Chief Medical Officer of resTORbio. Prior to joining resTORbio, Dr. Mannick was Executive Director in the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research where she led the clinical program that targets fundamental pathways regulating the biology of aging as a new approach to treating aging-related diseases. Prior to joining Novartis in 2010, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas and a faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology. Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program.
Visit website: https://www.restorbio.com/team_post_type/joan-mannick-m-d/
See also: resTORbio - Biopharmaceutical company developing therapeutics for aging-related diseases.
Joan Mannick is also referenced in the following:
Online webinar focused on longevity extension without health related issues organized by The New York Academy of Sciences with Nir Barzilai and Pinchas Cohen as keynote speakers.
Joan Mannick News
Tornado, new longevity biotech developing safer and effective mTOR inhibitors
Longevity Technology - 03-Mar-2022
Different flavours of rapalogs targeting different age-related conditionsRead more...
Longevity Leaders' latest report on how longevity is disrupting the world
Longevity Leaders (LSX) - 01-Jan-2020
An interesting collection of interviews and white-papers with industry leadersRead more...
Everyday drugs could give extra years of life
New Scientist - 01-Oct-2014
Rapamycin in mice The study was published in the Diabetes, Obesity and Metabolism journal.Read more...